Hi Ziad,
This is Professor Sir Mark Pepys' answer to your question:
The phase II study is currently being planned with the intention of starting in 2016. The intervention, the disease and the regulatory environment are all very complex so that the process is unavoidably slow. GSK will make the official announcement on the clinicaltrials.gov website when the trial opens. At the same time the NAC will be recruiting patients.
There is also an official joint statement from the NAC and GSK that is provided in answer to patient enquiries. I will post it here soon.
I hope that helps.